Amgen, Cytokinetics heart failure drug misses goal in study

By Ben Hirschler AMSTERDAM (Reuters) - An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leaving its future uncertain. Despite the setback in the 613-patient trial using an intravenous formulation of the medicine omecamtiv mecarbil in hospitals, Amgen said it would continue testing an oral version of the drug in a separate Phase II study. The combined results from the tests will determine whether the medicine advances into final Phase III testing or is discontinued. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/amgen-cytokinetics-heart-failure-drug-misses-goal-study-060113147--sector.html